No. As of September 2026, Baxter International Inc. (BAX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 66.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 15.3% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 66.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 15.3% / 33% · Receivables / Mkt Cap (36m) 13.8% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 66.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 15.3% / 33.33% · Receivables / Mkt Cap (24m) 13.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 46.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 10.2% / 33.33% · Receivables / Avg Assets (4Q) 9.19% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 44.3% / 33.33% · (Cash+ST Inv) / Total Assets 10.2% / 33.33% · (Cash+Recv) / Total Assets 19.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Baxter International Inc. (BAX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Baxter International Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
Baxter International Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Baxter International Inc. (NYSE: BAX) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $13.3B. The Maz Rating grades it against the other companies in its sector.
Baxter International Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $25.76, Baxter International Inc. trades at 1.1x sales and 2.0x book value, with an EV/EBITDA of 25.2. Over the last twelve months it generated about $11.6B of revenue and a net loss of $715M. It runs a gross margin of 30.1%, an operating margin of -1.9% and a net margin of -6.2%. It shows return on equity of -11.6%, return on invested capital of -1.3% and a free cash flow yield of 7.5%. On the balance sheet: a debt-to-equity ratio of 1.35 and a current ratio of 1.79. Over the past 52 weeks the share price ranged from $15.73 to $30.00, with a beta of 0.67.
Baxter International Inc. pays a dividend yielding 0.16%. Its Maz Dividend Score is 1.37 out of 5, ranked against the other dividend payers in its sector (Safety 3.37, Growth 1.10, Yield 2.17, Consistency 1.58).
36 Wall Street analyst ratings cover the stock: 14 Buy, 20 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.